Zhī tōng cái jīng APP learned that 2seventy bio (TSVT.US) announced the completion of an asset purchase agreement. According to the agreement, Novo-nordisk a/s (NVO.US) will acquire 2seventy bio's hemophilia A project. In addition, Novo-nordisk a/s will also acquire the rights to 2seventy bio's in vivo gene editing technology. The technology is used for autologous or allo-hematopoietic stem cell therapy for autoimmune diseases. 2seventy bio also stated that the team currently involved in the project will join Novo-nordisk a/s and continue to advance the technology. Boosted by this news, as of press time, 2seventy bio rose nearly 4% in pre-market trading on Thursday.

In return, 2seventy bio is eligible for a payment worth up to US$40 million. 2seventy bio stated that the transaction will help improve its commercialization and continued development of Abecma (idecabtagene vicleucel). According to the data, Abecma is a BCMA-targeted CAR T-cell therapy for multiple myeloma developed by 2seventy bio in collaboration with Bristol-Myers Squibb (BMY.US).